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Abstract
Objective: Little is known about the endoscopic features 
and clinical significance of small bowel (SB) lesions 
in primary intestinal follicular lymphoma (IFL). This 
study aimed to describe, based on a case series, detailed 
endoscopic features of SB lesions in IFLs and the 
relationship between clinical and histological stages. 
Methods: This retrospective study included 14 patients 
(8 females, median age, 61.5 years) newly diagnosed 
with IFL of SB. All patients underwent double balloon 
endoscopy (DBE), with both anterograde and retrograde 
approaches.
Results: The distribution of IFLs in the GI tract were 
stomach 7%(1/14), duodenal bulb 7% (1/14), second part 
of the duodenum 93% (13/14), third part of the duodenum 
86% (12/14), jejunum 93% (13/14), and ileum 43% (6/14). 
No colorectal lesions were detected. Multiple granules 
were the most frequently detected lesion, and were found 
in all patients. Nodule/mass lesions were detected in 5 
patients. Nodule/mass lesions and ileal lesions were highly 
associated with the Lugano international classification. 
Eleven of 14 patients received chemotherapy plus 
Rituximab. Ten of 11 patients achieved complete response 
(CR). One patient achieved partial response (PR), but later 
exhibited disease progression. Four patients experienced 
grade 3 or 4 neutropenia, but all recovered without 
permanent side effects. One patient that achieved CR 
exhibited progressive disease after 54 months. All patients 
survived for a median of 35 months.
Conclusions: DBE was necessary for the precise 
diagnosis of IFL involving the SB. Endoscopic features 
included a nodule/mass and ileal lesions, which were 
related to the clinical stage.
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INTRODUCTION
Fol l i cu la r  lymphoma (FL)  i s  the  second  mos t 
frequent lymphoma in western countries. It comprises 
approximately 20% of all non-Hodgkin lymphomas 
(NHLs)[1]. Primary intestinal follicular lymphoma 
(IFL) is a relatively rare entity among NHLs of the 
gastrointestinal tract. IFLs account for 3.6%-5.9% of all 
GastrointestinalNHLs [2-3]. 
Most patients with IFLs were asymptomatic or 
had vague GI symptoms and were diagnosed during 
a esophagogastricduodenoscopy (EGD) screening[4]. 
Recently, screening EGDs were widespread in Japan for 
the detection of early esophago-gastric cancers; thus, 
asymptomatic IFLs were occasionally detected by chance. 
Indeed, reports of IFLs in Japan have increased in the past 
few years [5-7]. 
Little is known about the natural history and prognosis 
of IFLs. Therefore, a standard therapeutic strategy 
for IFLs has not been established. In current practice, 
physicians typically choose treatment regimens that refer 
to nodal FLs. Before the general use of small intestinal 
endoscopies, surgical resection or radiotherapy were 
indicated for localized duodenal FLs[4]. Currently, small 
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intestinal endoscopies include the wireless capsule 
endoscopy (WCE) and the double-balloon endoscopy 
(DBE). 
Some IFL studies have demonstrated with DBE 
that involvement in the jejunum and ileum occurred 
frequently[5-7]; thus, localized treatments for IFLs should 
be reconsidered. However, there is little knowledge 
about the detailed endoscopic features and clinical 
significance of IFLs. The aim of this study was to 
describe, based on a case series, the detailed endoscopic 
features of small bowel (SB) lesions of IFLs with DBE, 
and to determine the relationship between the clinical 
and histological stages. Additionally, we evaluated the 
therapeutic choices, responses, and mid-term prognoses 
of this case series.
PATIENTS AND METHODS
Patients
A total of 14 patients (8 females, median age, 61.5 years) 
were newly diagnosed with FLs of the SB between 
October 2005 and June 2009. All patients underwent 
DBE, with both anterograde and retrograde approaches. 
All DBEs were performed by a single experienced 
endoscopist (KH), who used a double balloon endoscope 
(EN-450P5/T5, Fujifilm Co., Saitama, Japan). The 
diagnosis, endoscopic features, and treatments were 
retrospectively investigated. The diagnoses were grouped 
as either asymptomatic or symptomatic (e.g. abdominal 
pain) evaluations. Moreover, previous histories of EGD 
were investigated in the endoscopic database. 
Endoscopic Features of FLs
Endoscopic features of FLs were categorized as either 
multiple granules or a nodule/mass. Multiple granules 
were whitish in color and irregular in size, when located 
in the duodenum (Figure 1a) and the jejunum (Figure 1b); 
in contrast, they mimicked large-sized lymphoid follicles, 
when located in the ileum (Figure 1c). Nodules/masses 
were defined as lesions that protruded more than 1 cm 
from the intestinal wall (Figure 1d). 
Figure 1
Endoscopic Features of Primary Intestinal Follicular Lymphomas. (a) Whitish Multiple Granules Around the 
Papilla Vater, (b) Whitish Multiple Granules in the Jejunum, (c) Multiple Granules That Look Like Lymphoid 
Follicles in the Ileum, (d) A Nodule/Mass Lesion in the Jejunum
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Pathological Evaluation
Endoscopic biopsies were taken from all lesions suspected 
to be FLs to perform a definite diagnosis. Biopsy 
specimens showed that the proliferation of atypical 
lymphocytes had formed lymphoid follicles (Figure 2a). 
This proliferation was clearly evident in the high power 
field view (Figure 2b). Pathologically, diagnosis of FL 
was indicated when atypical lymphocytes were diffusely 
positive for CD20, bcl-2, and CD10 (Figure 2c), and 
negative for CD3, CD5, and cyclin D1. The histological 
grading of FLs was based on the criteria of Mann and 
Berard[8].
Figure 2
Pathological Findings of Primary Intestinal Follicular Lymphomas. (a) Low Power View Shows Multiple Follicles 
In The Jejunum (H&E, ×40), (b) High Power View Shows a Diffuse Proliferation of Atypical Lymphocytes of 
Small to Medium Sizes (H&E, ×400),(c) Low Power View Shows Lymphocytes Were Diffusely Positive for CD10 
(CD10, ×40)
Staging
In the s taging process ,  we included a  physical 
examination, laboratory data, chest and abdominal 
computed tomography (CT), total colonoscopy, bone 
marrow examination, and/or 18F-fluorodexyglucose 
positron emission tomography (18F-FDG-PET). The 
Lugano international classification[9] was used to identify 
the clinical stage and to analyze the association between 
clinical and endoscopic findings. 
TREATMENT AND RESPONSE
There was no standard therapy with strong evidence. 
Therefore, our strategy was based on inform and 
patient’s selection. In the localized stage (I and II1), 
we informed patients of multiple treatment choices, 
including watch and wait, rituximab monotherapy, and 
chemotherapy with rituximab. In advanced stages (II2– 
IV), we recommended chemotherapy with rituximab, 
on  pr inc ip le .  Regimens  of  chemotherapy were 
selected according to the patient’s general condition. 
Cyclophosphamide, doxorubicin, vincristine, and 
prednisone with rituximab (R-CHOP) were the primary 
regimen[10-11]. However, for older patients or patients 
with cardiovascular complications, doxorubicin was 
replaced with pirarubicin (R-THP-COP). In principle, 
6 to 8 cycles of chemotherapy were performed for each 
patient. Adverse effects that corresponded to grades 3–4 
in the Common Terminology Criteria for Adverse Events 
(CTCAE), Version 4.0, were evaluated throughout 
the chemotherapy course. Response to treatment was 
assessed by EGD, CT, and DBE, when necessary, every 
6-12 months. Responses were evaluated based on a 
Response Evaluation Criteria in Solid Tumors (RECIST) 
criteria, which included a complete response (CR), a 
partial response (PR), progressive disease (PD), and 
stable disease (SD)[12].
Follow-up examinations after treatments and during 
watchful waiting were annual assessment using EGD, CT 
and DBE.
RESULTS
Eleven patients were asymptomatic and IFL was detected 
by screening with an EGD; the other 3 patients presented 
with mild abdominal pain (Table 1). Ten of the 14 patients 
received an EGD before the diagnosis of FL. The median 
interval between disease initiation and detection was 12 
months (range: 7-25 months). Based on a retrospective 
review of endoscopic pictures from previous EGDs, we 
could point out lesions due to FL in 9 out of 10 patients 
(Table 1).
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Table 1
Clinical Features and Treatments of Intestinal Follicular Lymphomas
Case Age Sex Presentation Previous EGD Treatment regimen (course) Adverse effects (G3-4) Response Follow-up period
1 55 F Asymptomatic 25M(FL+) R(8)-CHOP(6) ― CR 62(S)
2 60 M Symptomatic No R(8)-CHOP(6) ― CR→PD 60(S)
3 69 M Asymptomatic 12M(FL+) R(8)-CHOP(6) ― PR→PD 57(S)
4 58 F Asymptomatic 12M(FL+) R(8)-CHOP(6) ― CR 53(S)
5 74 M Asymptomatic 12M(FL+) Watchful waiting ― SD 43(S)
6 52 M Symptomatic No R(6)-CHOP(6) ― CR 41(S)
7 54 F Asymptomatic 7M(FL+) R(8)-CHOP(6) ― CR 35(S)
8 66 M Asymptomatic 13M(FL+) R(6)-THP-COP(6) Neutropenia G3 CR 30(S)
9 62 F Asymptomatic 13M(FL+) Rituximab monotherapy(6) ― CR 27(S)
10 70 F Asymptomatic 12M(FL+) R(7)-THP-COP(6) Neutropenia G4 CR 29(S)
11 61 F Asymptomatic 19M（FL-） R(6)-CHOP(6) Neutropenia G4 CR 25(S)
12 81 F Symptomatic No R(6)-THP-COP(6) Neutropenia G4 CR 22(S)
13 80 F Asymptomatic 12M(FL+) Watchful waiting ― PD 20(S)
14 47 M Asymptomatic No R(6)-THP-COP(6) ― CR 19(S)
Note. FL: follicular lymphoma, R-CHOP: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone, R-THP-COP: 
Rituximab, Pirarubicin, Cyclophosphamide, Vincristine, and Prednisone, CR: complete response, PR: partial response, PD: progressive 
disease, SD: stable disease, S: survival
Endoscopic Features
The endoscopic features are summarized in Table 2. The 
FL involved different parts of the GI tract, including 
stomach 7% (1/14), duodenal bulbs 7% (1/14), second 
part of the duodenum 93% (13/14), third part of the 
duodenum 86% (12/14), jejunum 93% (13/14), and 
ileum 43% (6/14). No colorectal lesions were detected. 
The most frequent finding was multiple granules, which 
was detected in all patients. Nodule/mass lesions were 
detected in 5 patients. Erosion of the stomach was 
detected in only one patient with gastric involvement. 
A nodule/mass lesion and ileal lesions were highly 
associated with the Lugano international classification. 
Therefore, these findings were useful for estimating the 
Lugano international stage II1 or above. For instance, the 
sensitivity, specificity, positive predictive value (PPV), 
and negative predictive value (NPV) of a nodule/mass 
were 83.3%, 100%, 100%, and 88.9%, respectively, 
and for ileal lesions, they were 83.3%, 87.5%, 83.3% 
and 87.5%, respectively (Table 3). Meanwhile, no 
association was found between the histological grade 
and endoscopic features.
Table 2




Jejunum Ileum Stage Grade
Case Bulbus 2nd part 3rd part
1 ― ― MG, nodule/mass Nodule/mass MG, nodule/mass MG II2 2
2 ― ― MG MG MG ― I 1
3 ― MG MG MG MG MG IV 1
4 ― ― MG MG MG ― I 1
5 ― ― MG MG MG ― I 1
6 ― ― ― MG MG ― I 1
7 ― ― MG MG MG MG I 1
8 ― ― MG MG MG, nodule/mass ― II1 1
9 ― ― MG ― ― ― I 1
10 Erosion ― MG MG MG MG, nodule/mass IV 2
11 ― ― MG ― MG ― I 1
12 ― ― MG MG MG, nodule/mass MG II2 1
13 ― ― MG MG MG ― I 1
14 ― ― MG MG, nodule/mass MG, nodule/mass MG, nodule/mass II1 1
1(7%) 1(7%) 13(93%) 12(86%) 13(93%) 6(43%)
Note. MG: multiple granules
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Table 3
Estimating Lugano International Stage II1 or Above From Endoscopic Findings
Endoscopic findings Sensitivity Specificity PPV NPV
Nodule/mass 83.3%(5/6) 100%(8/8) 100%(5/5) 88.9%(8/9) 
Ileal lesion 83.3%(5/6) 87.5%(7/8) 83.3%(5/6) 87.5%(7/8) 
Note. PPV: positive predictive value, NPV: negative predictive value
Treatments and Responses
The treatments and responses are summarized in Table 1. 
Eleven of 14 patients received chemotherapy that included 
rituximab (R-CHOP or R-THP-COP). Ten of 11 patients 
achieved CR, and one patient achieved PR, but progressed 
later. Grade 3 or 4 neutropenia appeared in 4 patients, but 
all patients recovered without permanent side effects. One 
patient that achieved CR exhibited disease progression 
after 54 months, but he had survived with the disease 
at the 60-month follow-up. All patients that received 
chemotherapy survived to a median follow-up period of 
35 months. One patient’s condition progressed, but the 
others were stable with disease-free status. Two patients 
chose watch and wait; one of these maintained SD, but 
the other exhibited PD. Both patients that chose watchful 
waiting survived with the disease to a median follow-
up period of 31 months. One patient received rituximab 
monotherapy and achieved CR. He survived and exhibited 
a disease-free state at 27 months. Collectively, all patients 
survived to the follow-up periods.  
DISCUSSION
In this case series, most patients with IFLs were 
asymptomatic and were diagnosed based on the chance 
detection of duodenal lesions in an EGD screening. In 
a previous review on IFL, the authors described 150 
previously reported cases, where 43% were asymptomatic 
and 9% presented vague GI symptoms[4]. In that review, 
abdominal pain, intestinal obstruction, and intestinal 
bleeding were present in 29, 8, and 6 %, respectively [4].
In our series, IFLs were frequently overlooked. Our 
investigation of previous endoscopic pictures showed 
that 90% of patients that underwent previous EGDs had 
presented duodenal FL lesions that had been overlooked. 
Based on our results, to prevent overlooking IFLs, it is 
most important to check for multiple whitish granules in 
the second part of the duodenum. For the early diagnosis 
of IFLs, we found that two factors were important; first, 
careful observation must be performed with sufficient air 
infiltration of the duodenum; second, it is important to 
distinguish FLs from benign lymphoid follicles and other 
lesions with whitish villi.
In  the  present  s tudy,  we demonst ra ted  h igh 
involvement of the jejunum (93%) and ileum (43%). 
Most of these lesions were distributed multifocally. The 
frequencies we found were higher than those reported 
before the general use of small bowel endoscopy[13-15]. 
Recently, a few case series of IFL that had been diagnosed 
by DBE demonstrated a similar lesion distribution[5-7]. 
Those reports showed that the frequency of involvement 
was higher in the jejunum than in the ileum. Colonic 
involvement was never observed in our case series. This 
finding was consistent with those of other recent case 
series from Japan [5-7, 16]. Moreover, we observed one case 
with gastric involvement, which is considered very rare 
among small bowel lesions. In our endoscopic findings, 
the most frequent was multiple granules of various 
sizes. This is distinct from the characteristics of benign 
lymphoid follicles. The granules were whitish in color in 
the duodenum and jejunum. Granules in the duodenum 
tended to gather to the Papilla Vater[17]. On the other 
hand, the granules in ileum were the same color as the 
surroundings, and looked like uneven lymphoid follicles. 
In some cases, a nodule or mass formation was found with 
multiple granules, and these were accompanied by erosive 
or ulcerative changes. The findings also showed massive 
increases in lymphoma cells in local areas. 
In the present study, we found new knowledge for 
an association between endoscopic features and the 
clinical stage. Nodule/mass lesions and ileal lesions were 
both useful factors for estimating Lugano international 
stage II1 or above. On the other hand, it was difficult to 
estimate the histological grade from endoscopic findings. 
The histological grade of IFLs is important information 
for designing an adequate treatment strategy. Grade 3 
treatment should be similar to that for a diffuse large B 
cell lymphoma. However, grade 3 IFLs were observed 
at low frequency [4]. There was no grade 3 case in our 
case series. DBE offers the advantage of providing an 
opportunity for taking a biopsy specimen and diagnosing 
the histological grade. However, due to the low frequency 
of grade 3 IFLs, a WCE can be used in place of a DBE. 
The WCE is also considered to be effective for evaluation 
after treatment [18].  
The natural history and long-term prognosis of 
IFLs have not been demonstrated. In a case series with 
relatively small numbers of patients with or without 
treatment, the relapse-free median survival time was 31 to 
45 months (13,15) , similar to that of nodal FLs. On the 
other hand, an analysis of previously reported IFL cases 
showed a better prognosis than that for nodal FLs[16]. The 
median relapse-free survival after achieving CR was 98 
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months in 96 patients with IFL[4]. There have been no 
randomized controlled trials (RCTs) for testing treatments 
for IFLs. Therefore, the standard therapeutic strategy for 
IFLs has not been established. Currently, the therapies for 
IFL are based on the regimens for nodal FL, which include 
chemotherapy, monoclonal antibody therapy, radiotherapy, 
surgery, or combination therapies[19]. Recently, it was 
acknowledged that IFL tended to involve the small bowel; 
therefore, the localized therapies, like radiotherapy and 
surgery appear to be unsuitable for treating IFLs. Based 
on a few recent case series, including this study, rituximab 
plus chemotherapy demonstrated a more favorable 
complete response rate for IFL than for nodal FL (7). This 
suggested that a complete cure of IFL might be expected, 
except in the case of stage IV disease. In our limited data, 
R-CHOP achieved the highest complete response rate. 
Recently, watch & wait is considered a practical strategy 
for low-tumor-burden FL[20-21]. However, strong evidence 
was lacking for watch & wait for IFLs. Therefore, many 
type treatments were conducted in practice[20]. Rituximab 
monotherapy is hopeful for low toxic and good tumor 
response[20-21]. It will be important to conduct an RCT of 
IFLs. However, that represents a challenge, due to the 
rarity of the disease and the necessity of long follow-up 
periods (> 10 years). The limitation of this study was that 
it was a retrospective small case series and short follow-
up period. 
CONCLUSION
DBE was found to be necessary for a precise diagnosis 
of GI-FLs that involved the small intestine. Endoscopic 
features, including a nodule/mass and an ileal lesion were 
possibly associated with the clinical stage. 
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